NCHR’s Comments on Proposed Supplemental Guidance for CPSC Chronic Hazard Guidelines

NCHR criticizes CPSC’s revised proposal for chronic hazard guidelines for focusing on linear modeling that is not appropriate for endocrine disrupting chemical and for including a loophole that enables companies to do whatever they think is scientifically appropriate. We urge the CPSC to produce more explicit, rigorous guidelines based on sound science, since that is essential for the safety of consumers.

Read More »

NCHR Comments on FDA’s Draft Guidance on QTc Information in Human Prescription Drug and Biological Product Labeling

October 10, 2023, in response to FDA’s draft guidance on QTc product labeling to
correctly measure heartbeat contraction and relaxation, NCHR recommends that FDA specify a preferred method of calculating the QTc, provide methods for to improve
study design, and require studies of the impact of drug-drug and
drug-disease interactions. These changes to the guidance are needed to encourage industry to do the research needed to ensure the safety and effectiveness of their products.

Read More »

NCHR Comment on CPSC’s Proposed Study of Toddlers Using Smart Toys

October 6, 2023: The Consumer Product Safety Commission is responsible for ensuring that consumer products are safe. One of their jobs is to make sure toys are labeled to indicate the age of children for which they are safe and age-appropriate. In October 2023, NCHR reviewed a proposed CPSC study of new toys intended for ages 2-4 and expressed concerns that there were too few children in the proposed study to provide reliable, generalizable information about the use and safety of these toys for a diverse group of U.S. children.

Read More »